Evaluation of Different Perimetric Grids to Detect Central Visual Field Defect in Glaucoma Patients With Reduce Ganglion Cell Layer Thickness Measured by Spectral Domain OCT.

The aim of the study is to evaluate the agreement between three different grids in detecting central visual field defect in early glaucoma patients with reduced ganglion cell layer thickness.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS-Fondazione GB Bietti, Rome, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

glaucoma patients with glaucomatous optic nerve head defect and reduced ganglion cell layer thickness

Exclusion criteria

age<18 years
unable to read, understand and sign the written informed consent
unable to perform visual field test
advanced glaucoma with C/D>0.7
other causes of optic neuropathies
retinal or macular diseases
lens or corneal opacities
spherical refractive defect >± 6D
cylindric refractive defect >± 3D

Treatment and study plan

Primary outcomes

the agreement between 10-2 HFA and 24-2c HFA in detecting central visual field defect

Time frame: 12 month

central visual field is defined by the presence of a cluster of three test locations with significantly reduced sensitivity in a hemifield fo the pattern deviation plot.

Secondary outcomes

the agreement between 24-2c HFA and G1 Octopus in detecting central visual field defect

Time frame: 12 month

central visual field is defined by the presence of a cluster of three test locations with significantly reduced sensitivity in a hemifield fo the pattern deviation plot.

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Fondazione G.B. Bietti, IRCCS

Other

Registry information

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2029
First posted: Jan 29, 2024
Registry last updated: Sep 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting